Trial Profile

A Phase 1, Single and Multiple Ascending Dose and Food Effect Study of CG001419 Administered Orally to Evaluate Safety, Tolerability and Pharmacokinetics in Healthy Subjects

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 23 Feb 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

23 Feb 2026 Status changed from active, no longer recruiting to completed.
12 Dec 2025 According to Cullgen media release, company plans to submit an IND for CG001419 in early 2026.and, pending FDA allowance of the IND, initiate a Phase 2 study in acute pain in bunionectomy patients in the United States. In addition to studying CG001419 in pain applications, it is also being studied in a separate Phase 1 clinical trial in China in patients with solid tumors.
12 Dec 2025 Results presented in the Cullgen media release.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com